Eva Giné

8PUBLICATIONS
74CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nutrigenomics and personalised nutritionPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 14, 2026
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

|Jun 20, 2024
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.

Beatriz Rey-Búa, Carlos Grande, José J Sánchez Blanco

|Jan 14, 2022
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Eva Giné, Fátima de la Cruz, Ana Jiménez Ubieto

|Nov 30, 2021
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.

Pablo Mozas, Andrea Rivero, Alfredo Rivas-Delgado

|Sep 21, 2020
A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma.

Pablo Mozas, Andrea Rivero, Alfredo Rivas-Delgado

|May 18, 2018
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Guillem Clot, Pedro Jares, Eva Giné

Pageof 2

Frequent Collaborators

6 joint publications

Armando López-Guillermo

5 joint publications

Elías Campo

4 joint publications

Ferran Nadeu

3 joint publications

Neus Villamor